SRX HEALTH SOLUTIONS INC (SRXH) Fundamental Analysis & Valuation
NYSEARCA:SRXH • US08771Y4026
Current stock price
0.1195 USD
+0 (+1.7%)
At close:
0.1224 USD
+0 (+2.43%)
After Hours:
This SRXH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SRXH Profitability Analysis
1.1 Basic Checks
- In the past year SRXH has reported negative net income.
- SRXH had a negative operating cash flow in the past year.
- In the past 5 years SRXH reported 4 times negative net income.
- SRXH had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- SRXH has a worse Return On Assets (-20.05%) than 89.19% of its industry peers.
- Looking at the Return On Equity, with a value of -153.92%, SRXH is doing worse than 86.49% of the companies in the same industry.
- The Return On Invested Capital of SRXH (740.21%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.05% | ||
| ROE | -153.92% | ||
| ROIC | 740.21% |
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Operating Margin of SRXH (59.00%) is better than 100.00% of its industry peers.
- SRXH has a Gross Margin of 23.21%. This is comparable to the rest of the industry: SRXH outperforms 43.24% of its industry peers.
- SRXH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59% | ||
| PM (TTM) | N/A | ||
| GM | 23.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
2. SRXH Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SRXH is creating value.
- The number of shares outstanding for SRXH has been increased compared to 1 year ago.
- The number of shares outstanding for SRXH has been increased compared to 5 years ago.
- The debt/assets ratio for SRXH has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.35 indicates that SRXH is not in any danger for bankruptcy at the moment.
- SRXH's Altman-Z score of 5.35 is amongst the best of the industry. SRXH outperforms 81.08% of its industry peers.
- SRXH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.35 |
ROIC/WACC85.18
WACC8.69%
2.3 Liquidity
- SRXH has a Current Ratio of 0.80. This is a bad value and indicates that SRXH is not financially healthy enough and could expect problems in meeting its short term obligations.
- SRXH has a worse Current ratio (0.80) than 81.08% of its industry peers.
- SRXH has a Quick Ratio of 0.80. This is a bad value and indicates that SRXH is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of SRXH (0.74) is better than 64.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.74 |
3. SRXH Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 21.85% over the past year.
- SRXH shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.00%.
- Measured over the past years, SRXH shows a quite strong growth in Revenue. The Revenue has been growing by 17.56% on average per year.
EPS 1Y (TTM)21.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.81%
Revenue 1Y (TTM)60%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%-60.8%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. SRXH Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SRXH. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- SRXH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SRXH is cheaper than 97.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.54 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. SRXH Dividend Analysis
5.1 Amount
- No dividends for SRXH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SRXH Fundamentals: All Metrics, Ratios and Statistics
0.1195
+0 (+1.7%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)03-25 2026-03-25
Earnings (Next)05-13 2026-05-13
Inst Owners0.18%
Inst Owner Change1.51%
Ins Owners8.72%
Ins Owner Change0%
Market Cap42.81M
Revenue(TTM)55.96M
Net Income(TTM)-5.42M
Analysts82.86
Price Target10.2 (8435.56%)
Short Float %2.91%
Short Ratio0.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 12.15 | ||
| P/tB | 12.15 | ||
| EV/EBITDA | 1.54 |
EPS(TTM)-0.65
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.16
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.05% | ||
| ROE | -153.92% | ||
| ROCE | 936.98% | ||
| ROIC | 740.21% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 59% | ||
| PM (TTM) | N/A | ||
| GM | 23.21% | ||
| FCFM | N/A |
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
F-Score1
Asset Turnover2.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 393.08 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 5.35 |
F-Score1
WACC8.69%
ROIC/WACC85.18
Cap/Depr(3y)14.78%
Cap/Depr(5y)14.84%
Cap/Sales(3y)0.18%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.81%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)60%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%-60.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y653.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-176.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-177.1%
OCF growth 3YN/A
OCF growth 5YN/A
SRX HEALTH SOLUTIONS INC / SRXH Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SRX HEALTH SOLUTIONS INC (SRXH) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRXH.
Can you provide the valuation status for SRX HEALTH SOLUTIONS INC?
ChartMill assigns a valuation rating of 1 / 10 to SRX HEALTH SOLUTIONS INC (SRXH). This can be considered as Overvalued.
How profitable is SRX HEALTH SOLUTIONS INC (SRXH) stock?
SRX HEALTH SOLUTIONS INC (SRXH) has a profitability rating of 2 / 10.
Can you provide the dividend sustainability for SRXH stock?
The dividend rating of SRX HEALTH SOLUTIONS INC (SRXH) is 0 / 10 and the dividend payout ratio is 0%.